TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02487251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime Supports
Description: Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mealtime Supports
Description: Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Exposure
Description: Participants receive no supplemental information on family mealtimes beyond what is already currently received

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Exposure
Description: Participants receive no supplemental information on family mealtimes beyond what is already currently received
Study: NCT02880683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTronik CANS Therapy System
Study: NCT04367077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem
Description: intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion
Study: NCT00559663

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 70% dark chocolate
Description: The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels.
Study: NCT04698083

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiography ,Tomographic imaging
Description: Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
Study: NCT03752255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety measurement method
Description: Two different techniques (video or verbal information) will be examined about impacted third molar surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anxiety measurement method
Description: Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
Study: NCT02669407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: splanchnic nerve anesthesia with a local anesthetic
Description: regional nerve block of the splanchnic nerve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regional nerve block with a local anesthetic (Lidocaine)
Study: NCT00664183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitreosolve
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitreosolve
Description: Intravitreal injection
Study: NCT02840916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham laser acupuncture
Description: Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
Study: NCT02492698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
Study: NCT00745771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diractin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diractin
Study: NCT04924049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-assisted education
Description: Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
Study: NCT01113671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E (d-alpha-tocopheryl acetate)
Description: 100% natural source d-alpha-tocopheryl acetate in a soft gel cap

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: includes inactive Ingredients
Study: NCT02719314

Intervention type: DRUG
Intervention: Glucocorticoid treatment
Description: Glucocorticoid treatment

Intervention type: DRUG
Intervention: Glucocorticoid treatment
Description: Glucocorticoid treatment
Study: NCT00607061

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
Study: NCT02113410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit 'N' Fit Chair Yoga (SNFCY)
Description: Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program (HEP)
Description: Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
Study: NCT03532399

Intervention type: DRUG
Intervention: Bivalirudin
Description: CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or \> 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos_f/6317841), but will ultimately be determined by patient's primary provider.

Intervention type: DRUG
Intervention: Bivalirudin
Description: CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or \> 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos_f/6317841), but will ultimately be determined by patient's primary provider.

Intervention type: DRUG
Intervention: Bivalirudin
Description: CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or \> 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos_f/6317841), but will ultimately be determined by patient's primary provider.
Study: NCT01947153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Free combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Free combination
Study: NCT02859519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B
Description: MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MOB015B Vehicle
Description: MOB015B Vehicle without the active ingredient Terbinafine
Study: NCT02626650

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom elicitiation
Description: Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom elicitiation
Description: Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom elicitiation
Description: Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom elicitiation
Description: Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
Study: NCT01380288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivastigmine patch
Description: rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivastigmine patch
Description: rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
Study: NCT00661453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid and Levocarnitine
Description: Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
Study: NCT03620383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical Heat
Description: Warm heat pack applied topically in participant hand.
Study: NCT04544163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate- Fentanyl
Description: drug administration before intubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 4Mcg/kg
Description: drug administration with induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 2Mcg/kg
Description: drug administration with induction of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 2Mcg/kg
Description: drug administration with induction of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 2Mcg/kg
Description: drug administration with induction of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg
Description: drug administaration 90 sec before intubation
Study: NCT03447106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy
Description: This is a kind of traditional surgical method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic
Description: laparoscopic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic
Description: the Da Vinci robot assisted gastric resection
Study: NCT02301845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diatoms Shells
Description: Instillation of suspended diatom shells - 10 mg q12h
Study: NCT03888326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1x1 anodal tDCS
Description: 20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: 10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Robotic Rehabilitation
Description: 10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
Study: NCT01638403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigil
Description: Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: palcebo
Description: placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon.
Study: NCT02362425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03564834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Patients will receive laparoscopic gastrectomy within one week after randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: Patients will receive open gastrectomy within one week after randomization.
Study: NCT01313221

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical agents
Description: Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%
Study: NCT01013389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actifuse ABX
Description: bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INFUSE, plus master granules (MGG)
Description: bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
Study: NCT02105649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercise + Electrical stimulation of calf muscle

Intervention type: OTHER
Group type: OTHER
Intervention: selected physical therapy program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Study: NCT02298049

Intervention type: OTHER
Group type: OTHER
Intervention: Satiated / Pre-meal
Description: All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study: NCT00875277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102 cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102 Cream Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102 Plus Calcipotriol Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102 Plus Betamethasone Dipropionate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® Ointment
Study: NCT03354910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: House Call
Description: 60 to 90 minute home based educational intervention which will be administered by a health educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: House Call
Description: 60 to 90 minute home based educational intervention which will be administered by a health educator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentorship
Description: A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
Study: NCT02909309

Intervention type: DEVICE
Group type: OTHER
Intervention: JAWAC system + Capnoline + Spo2
Description: measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
Study: NCT03104283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: take apatinib orally until disease progression or appearance of unbearable toxicity
Study: NCT00995384

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Scan
Description: Cardiac CT with special attention to valves in Endocarditis patients.
Study: NCT06456086

Intervention type: BIOLOGICAL
Intervention: stimulation with EB virus
Description: stimulation with EB virus

Intervention type: BIOLOGICAL
Intervention: stimulation with EB virus
Description: stimulation with EB virus

Intervention type: BIOLOGICAL
Intervention: stimulation with EB virus
Description: stimulation with EB virus
Study: NCT03626831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab Prefilled Syringe
Description: Injection of study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Injection of placebo
Study: NCT01006616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: Navarixin 10 mg and 30 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: Navarixin 10 mg and 30 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: Navarixin 10 mg and 30 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to navarixin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to navarixin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to navarixin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic